Skip to main content
Publications
Limoncella G, Bartolini CC, Duran C, Girardi A, Hyeraci G, Arnau JR, Llorente A, Soriano LC, Martin-Perez M, Garcia-Poza P, Sanchez-Saez F, Sanfelix-Gimeno G, Nordeng H, Hurley E, Maglanoc LA, Holthuis E, Swart K, Lentile V, Tanaglia M, Brown J, Wing K, Schink T, Pajouheshnia R , Cunnington M, Sturkenboom M, Gini R. Extracting pregnancies from heterogeneous data sources in Europe: a novel algorithm in the conception project . Poster presented at the 2022 ICPE Conference; August 26, 2022. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2022 Sep 23; 31(S2):236-7. doi: 10.1002/pds.5518
Law EH, Galve-Calvo E, Wockel A, Parikh R , Kurosky SK, Derrien Ansquer V , Frugier G , Davis KL , Esterberg E , Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS) . Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Germing U, Goyal RK , Yucel A, Parikh RC , Jimenez M , Sluga-O'Callaghan M , Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States . Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576
Phiri K, Hallas J, Linder M, Margulia A , Suehs B, Arana A , Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder . Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Rebordosa C , Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J , Overbeek J, Ehrenstein V, Wallace L, Gilsenan A . Utilization of olodaterol and indacaterol in Europe . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864
Winfree KB, Ainsworth C, Njue A , Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A , Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review . Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Herring W , Gould IG, Casamassima G, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Italy . Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Herring W , Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain . Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Trantham L, Klein AB, Parikh RC , Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe . Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289
Kurosky S, Klein AB, Parikh RC , Trantham L, Zhang Y, Levine CA, Kaye JA. Clinical characteristics, treatment patterns, and health care resource utilization in unresectable, locally advanced, stage III non-small cell lung cancer: a medical record review study in the United States and Canada . Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.286